Novo Nordisk ran a nearly 4,000-patient Phase 3 Alzheimer's trial despite publicly stating it had a low probability of success. This strategy consumes valuable patient resources, raising ethical questions about whether a smaller, definitive Phase 2 study would have been a more responsible approach for the broader research ecosystem.

Biogen is proceeding to a Phase 3 trial with its tau-targeting Alzheimer's drug even though the mid-stage study technically failed its primary endpoint. The lowest dose performed best, contrary to expectations. This signals a strategy of pushing forward with mechanistically promising but complex drugs by positively framing ambiguous data.

Novo Nordisk's large semaglutide Alzheimer's trial failure highlights a critical design flaw: launching a massive study without first using smaller trials to validate mechanistic biomarkers and confirm central nervous system penetration. This serves as a cautionary tale for all CNS drug developers.

Acadia's experimental drug, Remlefanserin, was designed specifically to address the limitations of its marketed drug, Newplazid. By eliminating a side effect (QT prolongation) that capped the dosage of the original drug, the new molecule can be tested at higher, potentially more effective, exposures, demonstrating a strategy of iterative, targeted improvement in drug development.

Voyager CEO Al Sandrock suggests the 30% average efficacy of new Alzheimer's drugs isn't uniform. Instead, some patients may see a complete halt in progression while others see no benefit. He argues the next critical step is predicting these responders, which will determine whether future therapies like anti-tau agents should be added on or used as a replacement.

After several tau-targeting antibodies failed, including J&J's pazdenimab, confidence in blocking extracellular tau is waning. The field's new hope is Biogen’s Biv80, an antisense drug that prevents tau protein production at the mRNA level, a mechanism that has shown potential to reverse pathology in early data.

After Novo Nordisk's GLP-1 trial in Alzheimer's failed to show clinical benefit despite a 10% biomarker improvement, Coya is pursuing a combination therapy. They theorize that adding low-dose IL-2 can synergistically boost biomarkers to the 25-30% range, a level they believe is necessary to achieve clinically meaningful effects.

When questioned about discrepancies where a 24-week dose underperformed on the primary endpoint but was strong on secondary ones, the CEO avoided direct comparisons. Instead, he framed the results as a 'totality of evidence' supporting the drug's profile, a key communication tactic for presenting complex or imperfect data positively to investors and regulators.

Biogen's Phase 2 data for BIV80 is pivotal because its antisense mechanism targets Tau at the mRNA level, reducing all forms of the protein. This "turns off the faucet" approach provides a broad, definitive test of whether targeting Tau itself is a viable strategy for Alzheimer's, bypassing the complexity of its various forms.